The study is designed to evaluate MCY-M11, a mesothelin targeting CAR, in individuals with relapsed/refractory ovarian cancer and peritoneal mesothelioma. MaxCyte CEO Doug Doerfler said: “The initiation of
The post MaxCyte begins dosing in phase I solid tumors clinical trial appeared first on Pharma Business review.
Original Article: MaxCyte begins dosing in phase I solid tumors clinical trial